Atlas Bio raises $12.5M to test drugs on virtual patients, targeting the 70% drug failure rate. Read how it works and why ...
FDA proposes streamlined approvals for personalized gene editing as CMS expands therapy access model
FDA draft guidance lets sponsors add patient-specific variants to one BLA for personalized genome editing therapies. Read on for CMS access details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results